The WHO new guideline to control and eliminate human schistosomiasis: implications for the verification of transmission interruption and surveillance of Schistosoma japonicum in China  

作　　者：Jing Xu Shi-Zhu Li Jja-Gang Guo Xiao-Nong Zhou Amadou Garba Djirmay 

机构地区：[1]National Institute of Parasitic Diseases,Chinese Center for Disease Control and Prevention(Chinese Center for Tropical Diseases Research),Shanghai,China [2]NHC Key Laboratory of Parasite and Vector Biology,Shanghai,China [3]WHO Collaborating Centre for Tropical Diseases,Shanghai,China [4]National Center for International Research on Tropical Diseases,Shanghai,China [5]WHO Department of Control of Neglected Tropical Diseases,Geneva,Switzerland

出　　处：《Infectious Diseases of Poverty》2022年第4期1-3,共3页贫困所致传染病（英文）

基　　金：National Key Research and Development Program of China(No.2021YFC2300800,2021YFC2300804);National Science Foundation of China(Grant No.82073619)。

摘　　要：Schistosomiasis is one of the 20 neglected tropical diseases(NTDs)prioritized by World Health Organization(WHO).It is predominately distributed in subtropical and tropical areas of 78 countries and territories with approximate 800 million people at risk of infection and 241.3 million people requiring preventive chemotherapy(PC)[1].

关 键 词：SCHISTOSOMA CHEMOTHERAPY DISEASES 

分 类 号：R532.21[医药卫生—内科学] R181.3[医药卫生—临床医学]